|
A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients Clinical research trials and A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients. A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients  A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients
A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients
For Condition: Mycobacterium avium-intracellulare Infection,HIV Infections
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count < 100 cells/mm3.
Details:
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Required: - Anti-pneumocystis prophylactic therapy (dihydropteroate synthetase inhibitors with or without dihydrofolate reductase inhibitors, pentamidine). Allowed: - Concomitant anti-HIV therapy (AZT, ddI, ddC) or antifungal therapy (including azoles). Patients must have: - HIV infection. - CD4 count < 100 cells/mm3. - No MAC positive blood cultures within 1 month prior to study entry. - No symptoms suggestive of disseminated MAC infection (including unexplained diarrhea, fever, and night sweats) within 1 month of study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Positive PPD within 3 months prior to study entry (negative PPD defined as < 5 mm induration). - Chest x-ray suggestive of any active disease, in particular tuberculosis. - Known hypersensitivity to macrolide antibiotics. - Any other acute clinical condition likely to interfere with completion of the protocol. - Inability to care for self without considerable assistance and medical care. Concurrent Medication: Excluded: - Other investigational new drugs (except for foscarnet or ddC) unless prior agreement has been reached between the investigator and the Pfizer project physician. - Concomitant putative immunostimulants. Patients with the following prior conditions are excluded: History of MAC or Mycobacterium tuberculosis (MTb) infection. Prior Medication: Excluded within the past 4 weeks: - Any putative anti-MAC therapies including rifampin, rifabutin, clofazimine, ethambutol, cycloserine, ethionamide, amikacin, and ciprofloxacin or other quinolones thought to be active against MAC.
Total Enrollment:
Location and Contact Information:
Womack Army Med Ctr / Med Clinic
Fort Bragg, North Carolina, 283075000
United States
United States Air Force Med Ctr
Lackland Air Force Base, Texas, 782365300
United States
San Diego Naval Hosp
San Diego, California, 921345000
United States
Additional Information:
Study ID Numbers: 058I; 066-155
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002309
Other Hiv Infections Studies:
1. Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
2. A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
3. A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
4. Prospective Study of HIV Infection in Hemophiliacs
5. A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Fort Bragg Clinical Trials
A Study of Azithromycin in the Prevention of Mycobacterium avium Complex Disease (MAC) in HIV-Infected Patients
|
|
|
|
|
|
|
|
